MELT - MRI Evaluation of Lymphoma Treatment

University College, London58 enrolled

Overview

Patients who are newly diagnosed with Hodgkin's lymphoma will undergo disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo an extended MRI scan.

The trial will be a single centre cohort study in patients newly diagnosed with Hodgkin's lymphoma undergoing disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo advanced anatomical and functional MRI sequences.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphoma, Hodgkin

Eligibility

Sex: ALLMin age: 5 YearsMax age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 5 to 20 years (inclusive) with participant and parent/guardian informed consent * Histologically confirmed first presentation of Hodgkin's Lymphoma * Either entered into the Euronet PHL-C1 trial or LP1 trials OR not formally entered into the Euronet trials but treated on the chemotherapy regimens of the Euronet trials for classical and lymphocyte predominant Hodgkin Lymphoma Exclusion Criteria: * Contraindications to MRI (e.g. pacemaker) * Previous malignancy or previous chemotherapy or radiotherapy treatment for malignancy * Pregnancy or nursing

Locations (1)

University College London Hospital (UCLH)

London, United Kingdom

Outcomes

Primary Outcomes

The per site sensitivity and specificity of MRI for both nodal and extranodal sites and concordance in final disease stage with the multi-modality reference standard